Protocol Ledger

NCT04583423 · Phase II · TERMINATED

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

Interventional Phase II clinical trial protocol NCT04583423 sponsored by Merck & Co. in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-11 Enrollment: 183 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04583423
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)183 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04583423
Protocol FieldVerified Registry Value
NCT IdentifierNCT04583423
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment183 participants (ACTUAL)
Registered Start Date2020-11-11
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI